Letter to the editor: Role of adjuvant programmed death-1 blockade combined with chemotherapy in resected pancreatic ductal adenocarcinoma

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, with high rates of early recurrence even after curative-intent surgery and optimal adjuvant chemotherapy. While immune checkpoint inhibitors targeting programmed death-1 have transformed outcomes in several cancers, their efficacy in advanced PDAC has been limited, largely due to a profoundly immunosuppressive tumor microenvironment. In this context, the real-world cohort study by Cao et al in the World Journal of Gastrointestinal Oncology explores the clinical value of combining programmed death-1 inhibition with adjuvant chemotherapy in patients with resected PDAC. The study reports a significant improvement in recurrence-free and distant metastasis-free survival without a concomitant increase in severe toxicity. This article critically appraises these findings in light of existing literature, discusses their biological plausibility, and outlines future directions for biomarker-driven, prospective evaluation of adjuvant immunotherapy in PDAC.

Key Words: Pancreatic ductal adenocarcinoma; Adjuvant therapy; Programmed death-1 inhibitor; Immunotherapy; Recurrence-free survival; Real-world evidence

Core Tip: Although immune checkpoint inhibitors have shown minimal efficacy in advanced pancreatic cancer, the postoperative adjuvant setting may offer a biologically favorable window for immune intervention. A recent study suggested that combining programmed death-1 inhibition with chemotherapy after surgical resection may improve recurrence-related outcomes without excessive toxicity, providing a compelling rationale for prospective, biomarker-informed trials in this historically refractory disease.

TO THE EDITOR

Pancreatic ductal adenocarcinoma (PDAC) continues to pose a formidable clinical challenge, with a 5-year survival rate remaining below 12% despite advances in surgical techniques and systemic therapy[1]. Even among patients undergoing curative-intent resection, recurrence occurs in more than 80% of cases, most commonly as distant metastases within the first two years following surgery[2]. Contemporary adjuvant chemotherapy regimens, including modified FOLFIRINOX and gemcitabine-based combinations, have improved survival compared with historical standards, yet their capacity to prevent early relapse remains limited[2,3]. These sobering outcomes underscore the urgent need for novel adjuvant strategies capable of enhancing durable disease control.

Immune checkpoint inhibitors, particularly agents targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis, have reshaped the therapeutic landscape of multiple malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma[4,5]. However, PDAC has demonstrated striking resistance to immunotherapy, with objective response rates below 5% in unselected advanced-stage populations[6]. This resistance is widely attributed to a uniquely immunosuppressive tumor microenvironment characterized by dense desmoplasia, low tumor mutational burden, limited effector T-cell infiltration, and enrichment of immunoregulatory cell populations[7]. Consequently, current clinical guidelines restrict PD-1 inhibitor use to the rare subset of PDAC patients with microsatellite instability-high tumors[8].

Against this backdrop, the study by Cao et al[9] in the World Journal of Gastrointestinal Oncology is notable for examining PD-1 blockade in the adjuvant, rather than metastatic, setting. By focusing on patients with resected PDAC receiving postoperative chemotherapy with or without PD-1 inhibition, the authors explore whether minimal residual disease represents a therapeutic window in which immune modulation may exert meaningful clinical benefit.

METHODS SUMMARY

Cao et al[9] conducted a retrospective, single-center cohort study including 57 patients who underwent R0 or R1 resection for PDAC and received postoperative adjuvant therapy between 2021 and 2023. Patients were treated with either standard adjuvant chemotherapy alone or chemotherapy combined with a PD-1 inhibitor, specifically tislelizumab or camrelizumab. The primary endpoint was recurrence-free survival, with secondary endpoints including distant metastasis-free survival, overall survival, and treatment-related adverse events. Survival outcomes were assessed using Kaplan-Meier analyses and Cox proportional hazards modeling, with multivariable adjustment for clinically relevant covariates. Exploratory analyses examined dynamic changes in biomarkers such as carbohydrate antigen 19-9 and neutrophil-to-lymphocyte ratio. Although the magnitude of hazard ratio reduction appears substantial, effect sizes derived from small retrospective cohorts may reflect selection bias or unmeasured prognostic imbalances rather than true biological synergy[9]. Therefore, the findings should be considered hypothesis-generating rather than practice-changing at this stage, pending confirmation in adequately powered randomized trials.

KEY FINDINGS

The addition of PD-1 inhibition to adjuvant chemotherapy was associated with a significant prolongation of recurrence-free survival compared with chemotherapy alone, with a median recurrence-free survival of 21.0 months vs 9.0 months, respectively (hazard ratio = 0.37)[9]. Distant metastasis-free survival was similarly improved in the combination group, suggesting a potential effect on systemic disease control. Although overall survival favored the PD-1-treated cohort, this difference did not reach statistical significance, likely reflecting limited follow-up duration and sample size. Importantly, the incidence of grade ≥ 3 treatment-related adverse events was comparable between groups, indicating that the addition of PD-1 inhibition did not result in excessive toxicity.

While the reported recurrence-free survival benefit is compelling, several methodological considerations warrant caution. As a retrospective real-world cohort, treatment allocation may have been influenced by physician discretion, performance status, postoperative recovery, or socioeconomic factors, thereby introducing potential selection bias[9]. Moreover, imbalances in high-risk pathological features such as lymph node positivity, margin status, tumor differentiation, or perineural invasion could confound survival comparisons if not fully adjusted[9]. The heterogeneity of adjuvant chemotherapy regimens administered alongside PD-1 blockade further complicates interpretation, as different cytotoxic backbones may variably induce immunogenic cell death[10]. In addition, the use of two distinct PD-1 inhibitors, including tislelizumab and camrelizumab, introduces pharmacologic variability that may influence efficacy signals[11]. These factors underscore the exploratory nature of the findings and highlight the need for prospective randomized validation.

CRITICAL APPRAISAL

The findings reported by Cao et al[9] are biologically plausible and align with emerging concepts regarding the timing of immunotherapy. Surgical resection can reduce tumor burden and transiently remodel the tumor microenvironment, potentially enhancing antigen presentation and immune priming[12]. Furthermore, chemotherapy-induced immunogenic cell death may synergize with PD-1 blockade by promoting dendritic cell activation and cytotoxic T-cell recruitment[13,14]. Similar principles have underpinned the success of adjuvant immunotherapy in melanoma, renal cell carcinoma, and non-small cell lung cancer[4,15].

From a biochemical perspective, surgical tumor debulking reduces overall tumor burden and may partially diminish desmoplastic stromal density characterized by collagen I and fibronectin deposition, thereby lowering physical barriers to T-cell infiltration[16]. Adjuvant chemotherapy can induce immunogenic cell death, marked by calreticulin exposure, high-mobility group box 1 release, and extracellular adenosine triphosphate secretion, which enhance dendritic cell maturation and antigen presentation[14]. Cytotoxic therapy has also been associated with transient reductions in immunosuppressive cytokines such as transforming growth factor beta and interleukin 10, thereby attenuating regulatory T-cell and myeloid-derived suppressor cell activity[17]. Furthermore, metabolic suppressive pathways, including indoleamine 2,3-dioxygenase mediated tryptophan depletion and arginase-driven arginine scarcity, may be less dominant in minimal residual disease compared with bulky metastatic tumors[18]. Collectively, these alterations may create a more permissive immune milieu in which PD-1 blockade can restore cytotoxic T-cell function more effectively than in advanced disease.

At the molecular level, PD-1 engagement recruits the phosphatase Src homology 2 domain-containing protein tyrosine phosphatase 2 to its cytoplasmic immunoreceptor tyrosine-based switch motif, leading to dephosphorylation of ZAP70 and suppression of the phosphoinositide 3-kinase, protein kinase B, and mechanistic target of rapamycin signaling axis, thereby dampening T-cell activation and proliferation[19]. In the adjuvant setting, where antigen load is lower and T-cell exhaustion may be less profound, reversal of PD-1-mediated Src homology 2 domain-containing protein tyrosine phosphatase 2 signaling may more effectively restore ZAP70 phosphorylation and downstream effector function. Thus, PD-1 blockade in minimal residual disease may operate in a qualitatively distinct immunological landscape compared with metastatic pancreatic cancer.

Nevertheless, several limitations warrant careful consideration. The retrospective design introduces inherent risks of selection bias and unmeasured confounding, despite multivariable adjustment. The modest sample size limits statistical power, particularly for overall survival analyses and subgroup comparisons. Additionally, comprehensive immune and genomic profiling was not uniformly available, precluding identification of predictive biomarkers that could guide patient selection. These constraints underscore the need to interpret the observed benefits as hypothesis-generating rather than definitive evidence of efficacy.

FUTURE PERSPECTIVES

The study by Cao et al[9] highlights several avenues for future investigation. Prospective randomized trials are needed to validate the efficacy of adjuvant PD-1 inhibition in resected PDAC and to define optimal timing, duration, and combination strategies. Biomarker-driven approaches incorporating immune profiling, tumor mutational burden, and dynamic inflammatory markers may refine patient selection and enhance therapeutic precision[20,21]. Additionally, integration of perioperative immunotherapy strategies warrants exploration, given growing interest in immune modulation during the immediate postoperative period[22].

Biomarker stratification will be critical in translating these findings into clinical practice. PD-L1 expression, although historically low and heterogeneous in PDAC, may still provide predictive insights in minimal residual disease settings[23]. Tumor mutational burden is generally modest in pancreatic cancer, yet subsets harboring DNA damage repair deficiencies may exhibit enhanced immunogenicity and improved response to immune checkpoint blockade[24]. More promising are dynamic biomarkers such as circulating tumor DNA, which can detect minimal residual disease and identify patients at highest recurrence risk following surgery[25]. Integration of circulating tumor DNA monitoring into adjuvant immunotherapy trials may enable risk-adapted treatment escalation and refine patient selection. Furthermore, characterization of tumor-infiltrating lymphocytes and spatial immune architecture may clarify which patients derive durable immune surveillance from PD-1 blockade[26].

CONCLUSIONS

In conclusion, the emerging real-world data suggesting improved recurrence outcomes with adjuvant PD-1 blockade combined with chemotherapy in resected PDAC are provocative and biologically plausible. However, given the retrospective design, limited sample size, and potential confounding variables, these findings should be interpreted as hypothesis-generating. A mechanistically informed, biomarker-driven prospective trial incorporating molecular stratification and minimal residual disease monitoring will be essential to determine whether this strategy represents a true therapeutic breakthrough in early-stage pancreatic cancer.